tradingkey.logo

Camurus Announces FDA Acceptance Of NDA Resubmission For Oclaiz

ReutersJan 9, 2026 3:34 PM

- Camurus AB CAMX.ST:

  • CAMURUS ANNOUNCES FDA ACCEPTANCE OF NDA RESUBMISSION FOR OCLAIZ™ FOR THE TREATMENT OF ACROMEGALY

  • CAMURUS AB - PDUFA TARGET ACTION DATE SET FOR 10 JUNE 2026

  • CAMURUS AB: PRODUCT RECEIVED MARKETING AUTHORIZATION IN THE EU AND UK IN 2025 UNDER THE PRODUCT NAME OCZYESA, PRODUCT LAUNCH INITIATED IN THE EU

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI